Moving forward with immunotherapy: The rationale for anti-CTLA-4 therapy in melanoma

Community Oncology

Volumn 5, Issue 7, 2008, Pages 367-374

  Margolin, Kim ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BUDESONIDE; CETUXIMAB; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DIPHENHYDRAMINE; DIPHENOXYLATE; GLYCOPROTEIN GP 100; HYDROXYZINE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; MELANOMA VACCINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TEMOZOLOMIDE; TICILIMUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLITIS; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; MELANOMA; MONOTHERAPY; NONHUMAN; PRURITUS; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 48749090654     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70470-3     Document Type: Review

References (29)

1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915.
3. Faries MB. Evaluation of immunotherapy in the treatment of melanoma. Surg Oncol Clin N Am 2006;15:399-418.
4. Rituximab (Rituxan) [prescribing information]. South San Francisco, Calif: Genentech Inc.; 2007.
5. Cetuximab (Erbitux) [prescribing information]. Princeton, NJ; Bristol-Myers Squibb Company; 2007.
6. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-1212.
7. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618.
8. Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther 2005;7:588-597.
9. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol 2002;21:56.
10. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-4717.
11. Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 2005;23(16S):7525.
12. Atfia P, Phan GQ, Maker AV.et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
13. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/ II study. Ann Surg Oncol 2005;12:1005-1016.
14. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-463.
15. Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. J Clin Oncol 2005;23(16S):7524.
16. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J Clin Oncol 2007;25(18S):8523.
17. Hamid O, Urba WJ, Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol 2007;25(18S):8525.
18. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-8977.
19. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody in patients with advanced melanoma. J Clin Oncol 2007;25(18S):3000.
20. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-883.
21. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002;29:518-524.
22. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-8377.
23. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-2289.
24. Antonia S, Sosman J, Kirkwood JM, et al. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. J Clin Oncol 2007;25(18S):3038.
25. ClinicalTrials.gov. National Library of Medicine, US National Institutes of Health. Available at: http://www.clinicaltrials.gov. Accessed April 3, 2008.
26. Gomez-Navarro J, Sharma A, Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients with metastatic melanoma. J Clin Oncol 2006;24(18S):8032.
27. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864-872.
28. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-598.
29. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958-964.